Welcome to our dedicated page for Zimmer Biomet news (Ticker: ZBH), a resource for investors and traders seeking the latest updates and insights on Zimmer Biomet stock.
Zimmer Biomet Holdings, Inc. (ZBH) is a global innovator in musculoskeletal healthcare, delivering advanced orthopedic solutions for nearly a century. This news hub provides investors and medical professionals with timely updates on product developments, regulatory milestones, and strategic initiatives shaping the future of surgical care.
Track critical updates including quarterly earnings, FDA clearances for robotic surgery systems, and partnerships advancing AI-driven orthopedic solutions. Our curated feed consolidates press releases about joint reconstruction technologies, trauma care innovations, and global market expansions to inform your analysis of this medtech leader.
Discover how Zimmer Biomet’s integration of digital surgery platforms with traditional orthopedic expertise continues to redefine patient outcomes. Bookmark this page for direct access to verified updates about ZBH’s clinical advancements, without promotional commentary or speculative content.
Zimmer Biomet (NYSE: ZBH) announced the FDA granted Breakthrough Device Designation for its iodine-treated total hip replacement system on October 28, 2025. This is the first time the company has received this designation. The system integrates controlled-release Iodine Technology into the iTaperloc Complete and iG7 Hip System to help address periprosthetic joint infections (PJI). The device received PMDA approval in Japan in September 2025 as the world’s first approved orthopedic implant with this iodine treatment. The FDA program offers prioritized review and earlier agency interaction during regulatory review.
Zimmer Biomet (NYSE: ZBH) is showcasing robotics and musculoskeletal product innovations at the 2025 AAHKS Annual Meeting on Oct. 21, 2025. Highlights include the mBôs TKA System (CT-based, semi-autonomous) with U.S. FDA 510(k) clearance and a surgeon-guided autonomous version in clinical trials, the recently acquired Monogram surgeon-guided technology, and the ROSA Knee with OptimiZe pending FDA 510(k) clearance.
Other exhibits: TMINI miniature robotic system, ZBEdge analytics, mymobility care platform, Persona and Oxford knee technologies, Persona IQ smart knee, and multiple hip reconstruction tools.
Zimmer Biomet (NYSE: ZBH) launched two foot and ankle trauma implants on Oct 8, 2025: the Gorilla Pilon Fusion Plating System and the Phantom TTC Trauma Nail. Both products target complex pilon fractures and hindfoot injuries and are available to U.S. foot and ankle specialists.
The Gorilla system provides anatomically contoured dual-column plates, Type II anodized construction, percutaneous guides and long-shaft designs for primary tibiotalar fusion in severely comminuted pilon cases. The Phantom TTC Trauma Nail adds 150/300/350 mm lengths, PRECISION guide technology, up to 8 mm internal compression and Ø7.2/Ø5.0 threaded pegs.
Zimmer Biomet (NYSE: ZBH) completed its acquisition of Monogram Technologies on Oct 7, 2025, adding Monogram's AI-driven semi- and fully autonomous orthopedic robotics to Zimmer Biomet's robotics and navigation portfolio.
Deal consideration converted each Monogram share into $4.04 cash plus non-tradeable contingent value rights (CVRs) entitling holders to up to $12.37 in cash if specified product, regulatory, and revenue milestones are met through 2030. Monogram received FDA 510(k) clearance in March 2025 for a CT-based semi-autonomous TKA system, with commercialization targeted with Zimmer Biomet implants by early 2027. Monogram began a clinical study for a fully autonomous version in July 2025. Zimmer Biomet's ROSA platform is approaching 2,000 installations worldwide and ROSA Knee with OptimiZe has been submitted to the FDA with 510(k) anticipated later in 2025.
Zimmer Biomet (NYSE: ZBH) announced its Q3 2025 earnings webcast and conference call on Wednesday, November 5, 2025 at 8:30 a.m. ET. A news release with the quarterly results will be published the same day at 6:30 a.m. ET. The live audio webcast will be available on Zimmer Biomet's Investor Relations website at https://investor.zimmerbiomet.com and will be available for replay after the call.
U.S. and Canada dial-in: (800) 330-6710 with conference ID 7090861. International dial-in: +1 (213) 279-1505 with conference ID 7090861.
Zimmer Biomet (NYSE:ZBH) has received PMDA approval in Japan for the iTaperloc® Complete and iG7™ Hip System, marking a significant breakthrough as the world's first iodine-treated total hip replacement system. The innovative technology inhibits bacterial adhesion and prevents biofilm formation on implant surfaces.
The system addresses Periprosthetic Joint Infection (PJI), which affects 1-2% of primary total joint arthroplasty procedures and carries a mortality rate comparable to breast cancer (11%). The technology, developed by Professor Hiroyuki Tsuchiya, uses a controlled-release iodine layer through advanced anodization and electrophoresis.
This earlier-than-expected approval strengthens Zimmer Biomet's infection management solutions portfolio, combining the clinical heritage of the Taperloc Complete Hip System with the G7 Acetabular System's performance.
Zimmer Biomet (NYSE: ZBH) announced its participation in the American Orthopedic Foot and Ankle Society Annual Conference in Savannah from September 10-13, 2025. The company's subsidiary, Paragon 28, will showcase its comprehensive foot and ankle product portfolio at Booth #421.
Key innovations to be featured include the SMART 28℠ Case Management Portal with AI integration, APEX 3D S™ Stemmed Tibial Implant, Phantom® Fibula Nail System, and several other surgical solutions. The company will also host exclusive events including hands-on training sessions, an innovations dinner, and a networking event on September 11.
Zimmer Biomet (NYSE:ZBH) has strengthened its medical leadership with two key appointments. Dr. Jonathan M. Vigdorchik joins as Chief Medical Technology Advisor for Adult Reconstruction and Hip Implants, while Dr. Anand M. Murthi becomes Chief Medical Advisor for Shoulder, Sports, Extremities, and Trauma (S.E.T.).
Both advisors will contribute their clinical expertise to guide product development, enhance medical education initiatives, and serve as strategic liaisons between Zimmer Biomet and the surgical community. Dr. Vigdorchik is from Hospital for Special Surgery in New York City, and Dr. Murthi serves at MedStar Union Memorial Hospital in Baltimore.
Zimmer Biomet (NYSE:ZBH), a global medical technology leader, has announced its quarterly dividend for Q3 2025. The company's Board of Directors approved a cash dividend of $0.24 per share. The dividend will be paid on or around October 31, 2025 to stockholders of record as of the close of business on September 30, 2025.
Zimmer Biomet (NYSE:ZBH) announced its participation in the upcoming Annual Morgan Stanley Healthcare Conference. The company's management team will deliver a presentation on Monday, September 8, 2025, at 8:30 a.m. ET.
Investors can access the live webcast through Zimmer Biomet's Investor Relations website. The presentation will also be available for replay after the conference concludes.
FAQ
What is the current stock price of Zimmer Biomet (ZBH)?
What is the market cap of Zimmer Biomet (ZBH)?
